Status:
COMPLETED
Impact of Intestinal Microbiota on Uremic Toxins Productions
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
CKD
Uremia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Chronic renal failure (CKD) affects 3 million people in France and is characterized by the accumulation of uremic toxins (UTs) such as p-cresyl sulfate (PCS) and indoxyl sulfate (IS) which participate...
Eligibility Criteria
Inclusion
- Age between 18 and 80 years old
- Non diabetic (fasting blood glucose \<1.26 g / L, or lack of insulin or oral antidiabetic treatment)
- BMI between 18 and 30 kg / m²
- Patient with CKD stage 4-5 ( eDFG \< 30 ml/min/1.73m2 CKD-EPI)
- Not dialyzed
- No history of kidney transplant
- Patient followed in the nephrology department of Pr FOUQUE at the Lyon Sud hospital center
Exclusion
- Active inflammatory, infectious, cardiovascular or neoplastic disease
- Colectomy, resection of the small intestine or cholecystectomy
- Patient having received antibiotics, prebiotics, probiotics in the last 3 months.
- Patient using laxatives (more than 2 doses per day for the last 3 months)
- Known renal pathology or known urologic malformation (healthy volunteer only)
Key Trial Info
Start Date :
June 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 13 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04768309
Start Date
June 4 2021
End Date
July 13 2021
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lyon Sud University Hospital
Pierre-Bénite, Rhône, France, 69310